

Graeme I Murray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9087169/publications.pdf>

Version: 2024-02-01

126
papers

7,925
citations

44069

48
h-index

51608

86
g-index

127
all docs

127
docs citations

127
times ranked

10529
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of a prognostic signature in colorectal cancer using combinatorial algorithm-driven analysis. <i>Journal of Pathology: Clinical Research</i> , 2022, , .	3.0	1
2	Interleukin-27 Regulates the Function of the Gastrointestinal Epithelial Barrier in a Human Tissue-Derived Organoid Model. <i>Biology</i> , 2022, 11, 427.	2.8	5
3	Screen detection is a survival predictor independent of pathological grade in colorectal cancer. A prospective cohort study. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2021, 19, 20-26.	1.8	7
4	Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. <i>Gut</i> , 2021, 70, 544-554.	12.1	148
5	Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 361-377.	2.3	2
6	Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8^+ T cell infiltrate. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 495-506.	3.0	8
7	Pathological response post neoadjuvant therapy for locally advanced rectal cancer is an independent predictor of survival. <i>Colorectal Disease</i> , 2021, 23, 1326-1333.	1.4	4
8	Gut Mucosal Microbiome Signatures of Colorectal Cancer Differ According to BMI Status. <i>Frontiers in Medicine</i> , 2021, 8, 800566.	2.6	4
9	Novel biomarkers for risk stratification of Barrett's oesophagus associated neoplastic progression—epithelial HMGB1 expression and stromal lymphocytic phenotype. <i>British Journal of Cancer</i> , 2020, 122, 545-554.	6.4	14
10	Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. <i>British Journal of Cancer</i> , 2020, 123, 1280-1288.	6.4	45
11	Current concepts in tumour-derived organoids. <i>British Journal of Cancer</i> , 2020, 123, 1209-1218.	6.4	49
12	The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation. <i>BMC Cancer</i> , 2020, 20, 500.	2.6	20
13	The expression of brown fat-associated proteins in colorectal cancer and the relationship of uncoupling protein 1 with prognosis. <i>International Journal of Cancer</i> , 2019, 145, 1138-1147.	5.1	16
14	Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis. <i>Journal of Pathology</i> , 2019, 247, 629-640.	4.5	127
15	Can Haematology Blood Tests at Time of Diagnosis Predict Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer?. <i>Digestive Surgery</i> , 2019, 36, 495-501.	1.2	7
16	Colorectal Tumors Require NUA1 for Protection from Oxidative Stress. <i>Cancer Discovery</i> , 2018, 8, 632-647.	9.4	57
17	Proteomics for early detection of colorectal cancer: recent updates. <i>Expert Review of Proteomics</i> , 2018, 15, 55-63.	3.0	18
18	Deficiency in Protein Tyrosine Phosphatase PTP1B Shortens Lifespan and Leads to Development of Acute Leukemia. <i>Cancer Research</i> , 2018, 78, 75-87.	0.9	39

#	ARTICLE	IF	CITATIONS
19	PWE-010â€¦Defining interleukin-27 effects on the epithelial barrier â€œ a new therapeutic for IBD?. , 2018, , .		0
20	PTU-056â€¦Loss of cathelicidin (LL-37) is associated with colorectal cancer progression. , 2018, , .		0
21	PTU-040â€¦HMGB1 in the pathogenesis of colorectal cancer. , 2018, , .		0
22	Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes. Scientific Reports, 2018, 8, 12096.	3.3	55
23	Combined linkage and association analysis of classical Hodgkin lymphoma. Oncotarget, 2018, 9, 20377-20385.	1.8	8
24	TIAM1 Antagonizes TAZ/YAP Both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells. Cancer Cell, 2017, 31, 621-634.e6.	16.8	73
25	Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. Modern Pathology, 2017, 30, 1287-1298.	5.5	23
26	Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. British Journal of Cancer, 2017, 117, 203-209.	6.4	38
27	The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance. British Journal of Cancer, 2017, 116, 1612-1620.	6.4	19
28	Gefitinib and <i>EGFR</i> Gene Copy Number Aberrations in Esophageal Cancer. Journal of Clinical Oncology, 2017, 35, 2279-2287.	1.6	100
29	Integrative analysis of the colorectal cancer proteome: potential clinical impact. Expert Review of Proteomics, 2016, 13, 917-927.	3.0	19
30	The Hippo effector <i>TAZ</i> (<i>WWTR1</i>) transforms myoblasts and <i>TAZ</i> abundance is associated with reduced survival in embryonal rhabdomyosarcoma. Journal of Pathology, 2016, 240, 3-14.	4.5	40
31	Transporters for Antiretroviral Drugs in Colorectal CD4+ T Cells and Circulating β 27 Integrin CD4+ T Cells: Implications for HIV Microbicides. Molecular Pharmaceutics, 2016, 13, 3334-3340.	4.6	6
32	Progress in the development of protein biomarkers of oesophageal and gastric cancers. Proteomics - Clinical Applications, 2016, 10, 532-545.	1.6	11
33	Extending colonic mucosal microbiome analysisâ€”assessment of colonic lavage as a proxy for endoscopic colonic biopsies. Microbiome, 2016, 4, 61.	11.1	43
34	MICL controls inflammation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1386-1391.	0.9	40
35	β -Glucan exacerbates allergic airway responses to house dust mite allergen. Respiratory Research, 2016, 17, 35.	3.6	21
36	The expression and prognostic significance of <i>blc2</i> â€”associated transcription factor 1 in rectal cancer following neoadjuvant therapy. Histopathology, 2016, 68, 556-566.	2.9	17

#	ARTICLE	IF	CITATIONS
37	Drug transporter gene expression in human colorectal tissue and cell lines: modulation with antiretrovirals for microbicide optimization. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 372-386.	3.0	16
38	Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer. <i>Oncotarget</i> , 2016, 7, 46509-46527.	1.8	31
39	Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phosphate lyase determines chemotherapy resistance in gastroesophageal cancer. <i>BMC Cancer</i> , 2015, 15, 762.	2.6	38
40	Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma. <i>Molecular Cytogenetics</i> , 2015, 8, 78.	0.9	8
41	CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation. <i>International Journal of Experimental Pathology</i> , 2015, 96, 81-86.	1.3	15
42	Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis. <i>Journal of Pathology</i> , 2015, 237, 273-281.	4.5	201
43	Microbial Ligand Costimulation Drives Neutrophilic Steroid-Refractory Asthma. <i>PLoS ONE</i> , 2015, 10, e0134219.	2.5	34
44	A Comprehensive Study of Extramural Venous Invasion in Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0144987.	2.5	33
45	The Hippo signal transduction pathway in soft tissue sarcomas. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 121-129.	7.4	28
46	Biomarkers of colorectal cancer: Recent advances and future challenges. <i>Proteomics - Clinical Applications</i> , 2015, 9, 64-71.	1.6	52
47	The Expression and Prognostic Significance of Retinoic Acid Metabolising Enzymes in Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e90776.	2.5	42
48	Increased Lymph Node Yield in Colorectal Cancer Is Not Necessarily Associated with a Greater Number of Lymph Node Positive Cancers. <i>PLoS ONE</i> , 2014, 9, e104991.	2.5	11
49	Reduced LIMK2 expression in colorectal cancer reflects its role in limiting stem cell proliferation. <i>Gut</i> , 2014, 63, 480-493.	12.1	26
50	The role of gene regulatory networks in promoting cancer progression and metastasis. <i>Future Oncology</i> , 2014, 10, 735-748.	2.4	17
51	The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation. <i>Cancer Cell</i> , 2014, 26, 273-287.	16.8	152
52	The proteomics of formalin-fixed wax-embedded tissue. <i>Clinical Biochemistry</i> , 2013, 46, 546-551.	1.9	18
53	Progress in the identification of plasma biomarkers of colorectal cancer. <i>Proteomics</i> , 2013, 13, 2227-2228.	2.2	17
54	Lysyl Oxidase Plays a Critical Role in Endothelial Cell Stimulation to Drive Tumor Angiogenesis. <i>Cancer Research</i> , 2013, 73, 583-594.	0.9	114

#	ARTICLE	IF	CITATIONS
55	Proteomics of Bone and Soft Tissue Sarcomas. <i>Current Proteomics</i> , 2012, 9, 94-102.	0.3	2
56	Has the proteome of formalin-fixed wax-embedded tissue been unlocked?. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3395-3398.	0.7	2
57	Following the protein biomarker trail to colorectal cancer. <i>Colorectal Cancer</i> , 2012, 1, 93-96.	0.8	3
58	Cellular apoptosis susceptibility (chromosome segregation 1â€like, <i>CSE1L</i>) gene is a key regulator of apoptosis, migration and invasion in colorectal cancer. <i>Journal of Pathology</i> , 2012, 228, 471-481.	4.5	33
59	The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosisâ†. <i>Human Pathology</i> , 2011, 42, 393-402.	2.0	50
60	The Inflammatory Microenvironment in Colorectal Neoplasia. <i>PLoS ONE</i> , 2011, 6, e15366.	2.5	151
61	The Proteomics of Colorectal Cancer: Identification of a Protein Signature Associated with Prognosis. <i>PLoS ONE</i> , 2011, 6, e27718.	2.5	78
62	The use of formalin fixed wax embedded tissue for proteomic analysis: Table 1. <i>Journal of Clinical Pathology</i> , 2011, 64, 297-302.	2.0	39
63	Biomarkers for Colorectal Cancer: Identification Through Proteomics. <i>Current Proteomics</i> , 2010, 7, 212-221.	0.3	9
64	Current and emerging concepts in tumour metastasis. <i>Journal of Pathology</i> , 2010, 222, 1-15.	4.5	232
65	Profiling the expression of cytochrome P450 in breast cancer. <i>Histopathology</i> , 2010, 57, 202-211.	2.9	128
66	The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. <i>Histopathology</i> , 2009, 54, 820-828.	2.9	36
67	An overview of laser microdissection technologies. <i>Acta Histochemica</i> , 2007, 109, 171-176.	1.8	82
68	The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2006, 1765, 85-100.	7.4	134
69	Profiling markers of prognosis in colorectal cancer.. <i>Clinical Cancer Research</i> , 2006, 12, 1184-1191.	7.0	104
70	Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. <i>Journal of Pathology</i> , 2005, 205, 74-81.	4.5	184
71	Cytochrome P450 1B1: a novel anticancer therapeutic target. <i>Future Oncology</i> , 2005, 1, 259-263.	2.4	77
72	Cytochrome P450 Profile of Colorectal Cancer: Identification of Markers of Prognosis. <i>Clinical Cancer Research</i> , 2005, 11, 3758-3765.	7.0	152

#	ARTICLE	IF	CITATIONS
73	Profiling Cytochrome P450 Expression in Ovarian Cancer: Identification of Prognostic Markers. <i>Clinical Cancer Research</i> , 2005, 11, 7369-7375.	7.0	145
74	An Introduction to Laser-Based Tissue Microdissection Techniques. , 2005, 293, 3-7.		10
75	Matrix Metalloproteinase/Tissue Inhibitors of Matrix Metalloproteinase Phenotype Identifies Poor Prognosis Colorectal Cancers. <i>Clinical Cancer Research</i> , 2004, 10, 8229-8234.	7.0	151
76	The candidate oncogene ZNF217 is frequently amplified in colon cancer. <i>Journal of Pathology</i> , 2004, 204, 282-288.	4.5	51
77	Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 500-509.	0.8	70
78	Pharmacogenomics of Cytochrome P450 Enzymes in Tumours. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2004, 2, 243-254.	0.3	3
79	Cytochrome P450 enzymes: novel options for cancer therapeutics. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 363-71.	4.1	154
80	Quantitative analysis of the Ah receptor/cytochrome P450 CYP1B1/CYP1A1 signalling pathway. <i>Biochemical Pharmacology</i> , 2003, 65, 1663-1674.	4.4	39
81	New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. <i>Journal of Pathology</i> , 2003, 201, 528-534.	4.5	142
82	The Structure, Regulation, and Function of Human Matrix Metalloproteinase-13. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2002, 37, 149-166.	5.2	177
83	Tumour Cytochrome P450 and Drug Activation. <i>Current Pharmaceutical Design</i> , 2002, 8, 1335-1347.	1.9	121
84	Analysis of key cell cycle checkpoint proteins in colorectal tumours. <i>Journal of Pathology</i> , 2002, 196, 386-393.	4.5	75
85	Laser Capture Microdissection: Applications in Urological Cancer Research. <i>UroOncology</i> , 2002, 2, 33-35.	0.1	3
86	Proteomics in Urological Cancer Research. <i>UroOncology</i> , 2002, 2, 163-166.	0.1	0
87	REGULATION, FUNCTION, AND TISSUE-SPECIFIC EXPRESSION OF CYTOCHROME P450 CYP1B1. <i>Annual Review of Pharmacology and Toxicology</i> , 2001, 41, 297-316.	9.4	296
88	Spot the differences: proteomics in cancer research. <i>Lancet Oncology</i> , The, 2001, 2, 270-277.	10.7	91
89	Matrix metalloproteinases: a multifunctional group of molecules. <i>Journal of Pathology</i> , 2001, 195, 135-137.	4.5	48
90	Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. <i>International Journal of Cancer</i> , 2001, 94, 297-301.	5.1	23

#	ARTICLE	IF	CITATIONS
91	Cytochrome P450 CYP1B1 protein expression:. Biochemical Pharmacology, 2001, 62, 207-212.	4.4	153
92	The role of cytochrome P450 in tumour development and progression and its potential in therapy. Journal of Pathology, 2000, 192, 419-426.	4.5	103
93	Proteomics: a new approach to the study of disease. Journal of Pathology, 2000, 192, 280-288.	4.5	197
94	Cyclin D1 protein expression and gene polymorphism in colorectal cancer. International Journal of Cancer, 2000, 88, 77-81.	5.1	108
95	The role of cytochrome P450 in tumour development and progression and its potential in therapy. Journal of Pathology, 2000, 192, 419-426.	4.5	2
96	Immunohistochemical Localization of Cytochrome P450 CYP1B1 in Breast Cancer with Monoclonal Antibodies Specific for CYP1B1. Journal of Histochemistry and Cytochemistry, 1999, 47, 1457-1464.	2.5	103
97	Matrix metalloproteinases in tumour invasion and metastasis. Journal of Pathology, 1999, 189, 300-308.	4.5	565
98	Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours. Cancer Letters, 1999, 139, 199-205.	7.2	45
99	Eniluracil Treatment Completely Inactivates Dihydropyrimidine Dehydrogenase in Colorectal Tumors. Journal of Clinical Oncology, 1999, 17, 2439-2439.	1.6	60
100	Human matrix metalloproteinase-9 : activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form. FEBS Journal, 1998, 258, 37-43.	0.2	49
101	Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. Journal of Pathology, 1998, 185, 256-261.	4.5	244
102	Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. Journal of Pathology, 1998, 185, 256-261.	4.5	4
103	27 Cytochrome P450 in normal human brain and brain tumours. Biochemical Society Transactions, 1997, 25, S577-S577.	3.4	16
104	66 Theta-class glutathione S-transferases in human kidney and renal tumours. Biochemical Society Transactions, 1997, 25, S605-S605.	3.4	0
105	A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. , 1997, 183, 237-241.		106
106	Expression of a DNA binding protein in tumours. Biochemical Society Transactions, 1996, 24, 252S-252S.	3.4	0
107	Differential expression of CYP1A1 and CYP1B1 in human breast cancer. Biochemical Society Transactions, 1996, 24, 327S-327S.	3.4	10
108	Cytochrome P450 1B1 expression in human malignant tumours. Biochemical Society Transactions, 1996, 24, 328S-328S.	3.4	6

#	ARTICLE	IF	CITATIONS
109	Expression of matrix metalloproteinases in colorectal cancer. <i>Biochemical Society Transactions</i> , 1996, 24, 329S-329S.	3.4	2
110	Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. <i>Nature Medicine</i> , 1996, 2, 461-462.	30.7	404
111	Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. <i>Nature Medicine</i> , 1996, 2, 461-462.	30.7	240
112	Letters to the editor. <i>Journal of Pathology</i> , 1995, 176, 319-324.	4.5	4
113	The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. <i>Journal of Pathology</i> , 1995, 177, 147-152.	4.5	70
114	Cytochrome P450 CYP3A5 in the human anterior pituitary gland. <i>FEBS Letters</i> , 1995, 364, 79-82.	2.8	32
115	Expression of cytochrome P450 CYP1B1 in breast cancer. <i>FEBS Letters</i> , 1995, 374, 270-272.	2.8	107
116	Immunohistochemical localization of glutathione s-transferases in sarcomas. <i>Journal of Pathology</i> , 1994, 174, 83-87.	4.5	8
117	The expression of cytochrome P-450, epoxide hydrolase, and glutathione s-transferase in hepatocellular carcinoma. <i>Cancer</i> , 1993, 71, 36-43.	4.1	58
118	In situ PCR. <i>Journal of Pathology</i> , 1993, 169, 187-188.	4.5	16
119	Expression of xenobiotic metabolizing enzymes in breast cancer. <i>Journal of Pathology</i> , 1993, 169, 347-353.	4.5	80
120	Cytochrome P450 expression is a common molecular event in soft tissue sarcomas. <i>Journal of Pathology</i> , 1993, 171, 49-52.	4.5	19
121	Cytochrome P450IA expression in adult and fetal human liver. <i>Carcinogenesis</i> , 1992, 13, 165-169.	2.8	48
122	A Novel Method for Optimum Biopsy Specimen Preservation for Histochemical and Immunohistochemical Analysis. <i>American Journal of Clinical Pathology</i> , 1991, 95, 131-136.	0.7	14
123	The distribution of different forms of cytochrome P-450 in human liver. <i>Biochemical Society Transactions</i> , 1990, 18, 1202-1202.	3.4	9
124	Semi-thin? semi-thick?. <i>Journal of Pathology</i> , 1989, 158, 267-267.	4.5	0
125	Is wax on the wane?. <i>Journal of Pathology</i> , 1988, 156, 187-188.	4.5	10
126	Matrix metalloproteinases in tumour invasion and metastasis. , 0, .		1